Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.
Totally agree. They know that the results are going to be positive. This product has absolutely massive potential. One of the big players WILL snap this up.
50 p by mid December.
Futura Medical to Present Data on MED2005 for the Treatment of Erectile Dysfunction at the 20th Annual Fall Scientific Meeting of SMSNA and Host Advisory Meeting
15 October 2019
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that it will be presenting data on its DermaSys® drug delivery technology and lead product MED2005, a fast-acting, topical, nitroglycerin (GTN) gel for the treatment of erectile dysfunction ("ED")' at the 20th Annual Fall Scientific Meeting of Sexual Medicine Society of North America (SMSNA), on 24-27 October 2019 at the Omni Nashville Hotel, Nashville, Tennessee USA. Futura will also host its third Scientific Advisory Meeting with high profile US Key Opinion Leaders ("KOLs") in the field of erectile dysfunction.
Erectile dysfunction disrupts the lives of at least 1 in 5 men globally1, affecting the sexual and emotional health of around 27 million men and their partners in the US alone. There has been little innovation in ED treatments for over ten years and many patients continue to suffer dissatisfaction with existing treatments especially those looking for a fast-acting treatment that can form part of sexual foreplay or those contraindicated from using existing therapies.
Tim Holland, Director of Clinical Development at Futura Medical, will be presenting a poster (#114) entitled "Ultrasound Doppler Measurements of Penile Blood Flow as a Predictor of Clinical Efficacy" on Thursday 24 October at 3:20pm CDT. The presentation will be part of the "Erectile Dysfunction Medical/Surgical Moderated Posters" session held in the Broadway Ballroom A-B.
In addition, Futura will present cumulative safety data for MED2005 in an oral presentation (#031) entitled "Establishing the safety profile in sexual partners of a new topical nitroglycerin gel for the treatment of erectile dysfunction" on Saturday 26 October at 4:00pm CDT. The presentation will be part of the "Emerging Treatments for ED and PD" session held in Broadway Ballroom F.
James Barder, Chief Executive Officer of Futura Medical, said: "We are very pleased to share these findings on our lead programme MED2005 with the medical community at this prestigious meeting ahead of our Phase 3 data readout at the end of the year. MED2005 has the potential to be a highly differentiated therapy, especially for mild to moderate ED. Shown to be safe and fast-acting (5-10 minutes) with a favourable side effect profile - a key differentiator to other ED products on the market, which has seen very little innovation over the past ten years.
"We also look forward to hosting our third Advisory Board Panel meeting with eminent US Key Opinion Leaders in the field of erectile dysfunction and discussing this meaningful data and the on-going
Also remember we are fully funded for phase 3
We will have dips between now and December however there is a definite possibility that an offer will be made for this company before the phase 3 results.
We know that there is a 70% plus chance that we will achieve the phase 3 result that we desire. There aren't many opportunities of been involved in a product that will totally change the value of a company . This product has HUGE potential.
We are now very close to the results and there is always the possibility that the results will come early.
This share has the possibility to be worth £££s
Can't ever see this going back to 8/ 9p. Too risky to be out of this share .
Are you for real? There have been millions of shares bought in the last week . Don't let the MMs fool you . Watch the R & D seminar from yesterday on the Futura Medical website. Yes like all shares this will go up as well as down however the fundamentals are there now. They are very confident that the phase 3 trials will be successful. Ok this is at the end of the year but the SP will be at least 3 times where it is at currently.
The quote from the R & D seminar was "the chances of the phase 3 studies being successful are fairly high ". This is a no brainer. Onward and upward . This share will be worth ££££sss
Spot on.
There would be a LOT more volume with a leak . Have faith . This share has huge potential
Remember someone selling means somebody else is buying. This share has great potential
Watch this share go North on Monday when they let us know that everything is on track and they are very confident that this will get phase 3 approval.
That was 10 years ago lol
We first invested in this company approximately 110 years ago when this company had a sp of around 40p. A lot has happenend since that time .....some good and some bad, however the potential upside from this point it's huge.
Foxestocks: Totally agree.
Ok wasn't the perfect RNS however this company has loads more opportunities coming.
Here's the bounce coming
what an opportunity this is. 20% down and the news ain't that bad. rework required on the well ......that's it.
Look to get in about 13p
SP is gonna get clobbered .........simples
There are some decent buys going through. Plus 20p by the end of this week